Best of BS Opinion: Herbs need good marketing, second Covid-19 wave & more

Here are the best of Business Standard's opinion pieces for Monday

Exports, imports, economy, coronavirus, covid-19, vaccine
Illustration: Ajay Mohanty
Kanika Datta New Delhi
1 min read Last Updated : May 17 2021 | 6:30 AM IST
There is a health catastrophe playing out around us but the gloom about the Indian economy is overstated and it’s time to look to the future, writes Ajay Shah. The present holds clues to the way forward for decision makers in firms: in vaccination and in exports. He explains why here.
 
In other views today:

Tamal Bandyopadhyay suggests that there’s a simple solution to the chronic underperformance of asset reconstruction companies. Break the cosy relationship between banks and ARC, he says. Read his analysis here
 
Surinder Sud says the mostly unorganised, unregulated, and non-transparent nature of the business of cultivation of herbs is hampering the development of a more lucrative market opportunity. Read it here
 
The top edit examines Q4 corporate results and warns that the second wave of the pandemic could derail recovery. Read it here
 
The second edit says till vaccine supply improves, India must also focus on a flexible and supportive medical infrastructure. Read it here
 

QUOTE OF THE DAY

“We are looking to press a pause button on some of our non-priority spending”

Government official to Reuters

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusBS OpinionCurated ContentVaccinationVaccineIndian exportsIndian EconomyIndian companiesIndia IncQ4 Resultscorporate earningsAsset reconstruction companies ARCsHerbs

Next Story